Russell Investments Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.66M | Sell |
107,372
-14,039
| -12% | -$334K | ﹤0.01% | 1715 |
|
|
2025
Q4 | $2.83M | Sell |
121,411
-9,645
| -7% | -$215K | ﹤0.01% | 1673 |
|
|
2025
Q3 | $2.58M | Sell |
131,056
-40,339
| -24% | -$830K | ﹤0.01% | 1726 |
|
|
2025
Q2 | $3.72M | Buy |
171,395
+29,642
| +21% | +$700K | ﹤0.01% | 1391 |
|
|
2025
Q1 | $3.44M | Sell |
141,753
-34,506
| -20% | -$777K | ﹤0.01% | 1387 |
|
|
2024
Q4 | $3.68M | Buy |
176,259
+2,471
| +1% | +$53.1K | 0.01% | 1324 |
|
|
2024
Q3 | $3.45M | Sell |
173,788
-41,749
| -19% | -$774K | 0.01% | 1387 |
|
|
2024
Q2 | $3.34M | Sell |
215,537
-22,207
| -9% | -$346K | 0.01% | 1362 |
|
|
2024
Q1 | $3.79M | Buy |
237,744
+45,863
| +24% | +$691K | 0.01% | 1292 |
|
|
2023
Q4 | $3.23M | Buy |
191,881
+10,013
| +6% | +$137K | 0.01% | 1356 |
|
|
2023
Q3 | $2.13M | Sell |
181,868
-14,522
| -7% | -$194K | ﹤0.01% | 1513 |
|
|
2023
Q2 | $2.64M | Sell |
196,390
-166,127
| -46% | -$2.39M | 0.01% | 1408 |
|
|
2023
Q1 | $6.01M | Buy |
362,517
+86,231
| +31% | +$1.42M | 0.01% | 1024 |
|
|
2022
Q4 | $5.14M | Sell |
276,286
-19,334
| -7% | -$298K | 0.01% | 1084 |
|
|
2022
Q3 | $3.79M | Sell |
295,620
-143,061
| -33% | -$1.7M | 0.01% | 1199 |
|
|
2022
Q2 | $3.07M | Buy |
438,681
+35,066
| +9% | +$257K | 0.01% | 1352 |
|
|
2022
Q1 | $3.34M | Sell |
403,615
-64,607
| -14% | -$457K | 0.01% | 1371 |
|
|
2021
Q4 | $3.17M | Buy |
468,222
+19,086
| +4% | +$126K | 0.01% | 1532 |
|
|
2021
Q3 | $2.38M | Sell |
449,136
-35,003
| -7% | -$191K | ﹤0.01% | 1727 |
|
|
2021
Q2 | $2.78M | Sell |
484,139
-176,036
| -27% | -$908K | ﹤0.01% | 1718 |
|
|
2021
Q1 | $3.04M | Buy |
660,175
+214,455
| +48% | +$852K | 0.01% | 1631 |
|
|
2020
Q4 | $1.49M | Buy |
445,720
+38,077
| +9% | +$128K | ﹤0.01% | 1912 |
|
|
2020
Q3 | $1.21M | Buy |
407,643
+94,586
| +30% | +$370K | ﹤0.01% | 1975 |
|
|
2020
Q2 | $1.44M | Sell |
313,057
-6,928
| -2% | -$31.1K | ﹤0.01% | 1836 |
|
|
2020
Q1 | $1.23M | Buy |
319,985
+80,329
| +34% | +$330K | ﹤0.01% | 1744 |
|
|
2019
Q4 | $896K | Buy |
+239,656
| New | +$1.12M | ﹤0.01% | 2156 |
|
|
2018
Q4 | – | Sell |
-3,264
| Closed | -$12K | – | 2934 |
|
|
2018
Q3 | $12K | Sell |
3,264
-9,723
| -75% | -$30.5K | ﹤0.01% | 2921 |
|
|
2018
Q2 | $41K | Sell |
12,987
-3,908
| -23% | -$11.9K | ﹤0.01% | 2832 |
|
|
2018
Q1 | $40K | Hold |
16,895
| – | – | ﹤0.01% | 2843 |
|
|
2017
Q4 | $68K | Sell |
16,895
-801
| -5% | -$2.65K | ﹤0.01% | 2836 |
|
|
2017
Q3 | $44K | Hold |
17,696
| – | – | ﹤0.01% | 2866 |
|
|
2017
Q2 | $49K | Buy |
+17,696
| New | +$36.9K | ﹤0.01% | 2881 |
|
Other funds holding CPRX
VCM
DM
VPM
Russell Investments Group's CPRX Position: Q1 2026 in Review
Russell Investments Group reduced its Catalyst Pharmaceutical (CPRX) stake by 12% in Q1 2026, selling an estimated $334K and leaving 107,372 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1715.
Russell Investments Group first reported a position in CPRX in Q2 2017 and has held it in 32 quarters since. The position peaked at $6.01M in Q1 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Russell Investments Group held 107,372 shares of Catalyst Pharmaceutical worth $2.66M as of Q1 2026.
- Russell Investments Group sold 14,039 Catalyst Pharmaceutical shares in Q1 2026, an estimated $334K.
- Catalyst Pharmaceutical made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #1715 holding.
- Russell Investments Group first reported a position in Catalyst Pharmaceutical in Q2 2017 and has held it in 32 quarters since.
- Russell Investments Group's Catalyst Pharmaceutical position peaked at $6.01M in Q1 2023.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.